Emerging studies suggest this peptide, a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may represent a promising advancement for obesity loss . Early human tests have indicated substantial losses in visceral tissue, conceivably outperforming current body composition therapies . Nevertheless , addi